scispace - formally typeset
Search or ask a question
Institution

Ochsner Medical Center

HealthcareNew Orleans, Louisiana, United States
About: Ochsner Medical Center is a healthcare organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Heart failure. The organization has 980 authors who have published 1159 publications receiving 49961 citations. The organization is also known as: Ochsner Hospital & Ochsner Foundation Hospital.


Papers
More filters
Journal ArticleDOI
TL;DR: There were week or null relationships between tea consumption and mortality due to all-cause, CVD disease or cancer were observed in ACLS, and tea drinkers had a survival advantage.
Abstract: Background: A small change in tea consumption at population level could have large impact on public health However, the health benefits of tea intake among Americans are inconclusiveObjective: To

13 citations

Journal ArticleDOI
TL;DR: The aim of this literature review is to summarize the available first- and second-line GEPNEC therapy, outline future treatments, and highlight the vast gap in the literature.
Abstract: Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) are a rare neoplasm with a bleak prognosis. Currently there are little prospective data available for optimal treatment. This review discusses the current available regimens and the future direction for the treatment of GEPNECs. Treatment plans for GEPNECs are often adapted from those devised for small cell lung cancer; however, differences in these malignancies exist, and GEPNECs require their own treatment paradigms. As such, current first-line treatment for GEPNECs is platinum-based chemotherapy with etoposide. Studies show that response rate and overall survival remain comparable between cisplatin and carboplatin versus etoposide and irinotecan; however, prognosis remains poor, and more efficacious therapy is needed to treat this malignancy. Additional first-line and second-line treatment options beyond platinum-based chemotherapy have also been investigated and may offer further treatment options, but again with suboptimal outcomes. Recent U.S. Food and Drug Administration approval of peptide receptor radionuclide therapy in low- and intermediate-grade neuroendocrine tumors may open the door for further research in its usefulness in GEPNECs. Additionally, the availability of checkpoint inhibitors lends promise to the treatment of GEPNECs. This review highlights the lack of large, prospective studies that focus on the treatment of GEPNECs. There is a need for randomized control trials to elucidate optimal treatment regimens specific to this malignancy. IMPLICATIONS FOR PRACTICE: There are limited data available for the treatment of poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) because of the rarity of this malignancy. Much of the treatment regimens used in practice today come from research in small cell lung cancer. Given the poor prognosis of GEPNECs, it is necessary to have treatment paradigms specific to this malignancy. The aim of this literature review is to summarize the available first- and second-line GEPNEC therapy, outline future treatments, and highlight the vast gap in the literature.

13 citations

Journal ArticleDOI
TL;DR: This research presents a novel and scalable approach to personalized medicine that aims to provide real-time information about thephysiology of central giant cell granuloma and its role in chronic disease.

13 citations

Journal ArticleDOI
TL;DR: It is shown that topical TXA is safe and effective for use in both stages of revision TKA for PJI and doesn't appear to negatively effect on the treatment of PJI in patients and did not increase the reinfection, complication, or mortality rate.
Abstract: Tranexamic acid (TXA) has been shown to decrease hemoglobin loss and reduce the need for transfusions in primary hip and knee arthroplasty. Our study evaluated the safety and efficacy of topical TXA in revision TKA for periprosthetic joint infection (PJI). We performed a retrospective review of patients who underwent removal of hardware with antibiotic spacer placement (stage 1) and/or revision TKA (stage 2) for PJI at our institution between September 2007 and July 2013. During that time, 49 patients underwent stage-1 procedures (20 knees with TXA, 29 without TXA) and 47 patients underwent stage-2 revisions (28 with TXA, 19 without TXA). We evaluated hemoglobin loss, need for transfusion, reinfection rate, length of stay (LOS), complications, and mortality with and without the use of TXA in these patients. All data sets were analyzed with a two-sample t-test. Average follow-up was 3.15 years (range, 1-7 years). TXA use led to a significantly lower percentage drop in the postoperative lowest hemoglobin compared with the preoperative hemoglobin in stage-1 surgeries (19.8 vs. 30.05%, p = 0.0004) and stage-2 revisions (24.5 vs 32.01%, p = 0.01). In both groups, TXA use was associated with a significant reduction in transfusion rates (stage-1, 25 vs 51.7%, p = 0.04; stage-2, 25 vs. 52.6%, p = 0.05). There was a nonstatistical decreased LOS in both groups in which TXA was used (stage 1, 5.15 vs. 6.72 days, p = 0.055; stage 2, 5.21 vs. 6.84 days, p = 0.09). There was no difference in the reinfection rate (4 vs. 4, p = 0.56) or mortality rate between groups (0 vs. 2 non-TXA group). A single upper extremity deep vein thrombosis occurred in a stage-1 patient who received TXA, and no pulmonary embolism occurred. We show that topical TXA is safe and effective for use in both stages of revision TKA for PJI. Previous studies have shown TXA to aggravate a staphylococcal infection in mice; however, topical TXA doesn't appear to negatively effect on the treatment of PJI in our patients and did not increase the reinfection, complication, or mortality rate.

13 citations

Journal ArticleDOI
TL;DR: Idiopathic interstitial pneumonias include a group of nonneoplastic, noninfectious lung diseases with a diverse spectrum of pulmonary abnormalities with some degree of interstitial cellular infiltration and/or collagen deposition.
Abstract: Idiopathic interstitial pneumonias (IIP) include a group of nonneoplastic, noninfectious lung diseases with a diverse spectrum of pulmonary abnormalities. The term is somewhat descriptive and inaccurate, because not all diseases classified as being in this category are limited to the interstitium, nor is the etiology entirely idiopathic. However, most of the diseases have some degree of interstitial cellular infiltration and/or collagen deposition (1). There have been numerous previous attempts at classifying this group of diseases (2–4). In 1969, Liebow and Carrington (3) first classified chronic interstitial pneumonias into five separate categories. Those categories are:

13 citations


Authors

Showing all 993 results

NameH-indexPapersCitations
Carl J. Lavie106113549318
Michael R. Jaff8244228891
Michael F. O'Rourke8145135355
Mandeep R. Mehra8064431939
Richard V. Milani8045423410
Christopher J. White7762125767
Bruce A. Reitz7433318457
Robert C. Bourge6927324397
Sana M. Al-Khatib6937717370
Hector O. Ventura6647816379
Andrew Mason6336015198
Aaron S. Dumont6038613020
Philip J. Kadowitz5537911951
David W. Dunn541958999
Lydia A. Bazzano5126713581
Network Information
Related Institutions (5)
Henry Ford Hospital
12.4K papers, 465.3K citations

80% related

Cleveland Clinic
79.3K papers, 3.4M citations

77% related

Cedars-Sinai Medical Center
26.4K papers, 1.2M citations

77% related

Vanderbilt University Medical Center
34.6K papers, 1.1M citations

76% related

Hospital of the University of Pennsylvania
14K papers, 459.9K citations

76% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20231
202223
2021120
2020117
2019102
201886